Search results
Showing 1 to 15 of 17 results for ruxolitinib
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)
Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.
Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.
Show all sections
In development Reference number: GID-TA11760 Expected publication date: TBC
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.
Show all sections
Sections for TA840
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Ruxolitinib for treating moderate atopic dermatitis [ID6602]
Awaiting development Reference number: GID-TA11809 Expected publication date: TBC
Awaiting development Reference number: GID-TA11494 Expected publication date: TBC
Discontinued Reference number: GID-TA11007
Discontinued Reference number: GID-TA10133
Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
This guidance has been updated and replaced by NICE technology appraisal guidance TA921.
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)
This guidance has been updated and replaced by NICE technology appraisal guidance 386.